Reproductive endocrine and endometrial effects of raloxifene hydrochloride, a selective estrogen receptor modulator, in women with regular menstrual cycles

Journal of Clinical Endocrinology and Metabolism

Volumn 83, Issue 1, 1998, Pages 6-13

  Baker, Valerie L ^a   Draper, Michael ^b   Paul, Sofia ^b   Allerheiligen, Sandy ^b   Glant, Michael ^c   Shifren, Jan ^a   Jaffe, Robert B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c Diagnostic Cytology Laboratories   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; RALOXIFENE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BONE TURNOVER; DRUG EFFECT; DRUG RECEPTOR BINDING; ESTROGEN THERAPY; FEMALE; HORMONE ACTION; HORMONE RELEASE; HUMAN; HUMAN EXPERIMENT; LUTEAL PHASE; MENSTRUAL CYCLE; NORMAL HUMAN; POSTMENOPAUSE; PRIORITY JOURNAL;

ADULT; CHORIONIC GONADOTROPIN; DOUBLE-BLIND METHOD; ENDOMETRIUM; ESTRADIOL; ESTROGEN ANTAGONISTS; FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; LUTEINIZING HORMONE; MENSTRUAL CYCLE; MIDDLE AGED; OVULATION; PIPERIDINES; PROLACTIN; RALOXIFENE; RANDOM ALLOCATION; RECEPTORS, ESTROGEN; VAGINA;

EID: 0031790699     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.83.1.6     Document Type: Article

References (28)

1. Yang NN, Venugopalan M, Hardikar S, Glasebrook A. 1996 Identification of an estrogen response element activated by metabolites of 17β-estradiol and raloxifene. Science. 273:1222-1225.
2. Black LJ, Sato M, Rowley ER, et al. 1994 Raloxifene (LY139481) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest. 93:63-69.
3. Draper MW, Flowers DE, Huster WJ, Neild JA, Harper KD, Arnaud C. 1996 A controlled trial of raloxifene (LY 139481) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Miner Res. 11:835-842.
4. Fisher B, Costantino JP, Redmond CK, et al. 1994 Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst. 86:527-537.
5. Huster WJ, Boss SM, Glant MD, Eisenhut CC, Neild JA, Draper MW. 1996 Raloxifene does not cause endometrial proliferation in postmenopausal women. J Soc Gynecol Invest. 3(Suppl 2):142A.
6. Hale O, Miles R, Howe S, Walker C, Fuchs-Young R. 1996 Raloxifene, a selective estrogen receptor modulator, inhibits estrogen stimulated proliferation of leiomyoma cells in culture. J Soc Gynecol Invest. 3(Suppl 2):335A.
7. Porter KB, Tsibris JCM, Porter SW, et al. 1996 Raloxifene causes rapid regression of abdominal wall leiomyomas in the estrogen-induced guinea pig model. J Soc Gynecol Invest. 3(Suppl 2):147A.
8. Draper MW, Flowers DE, Neild JA, Huster WJ, Zerbe RL. 1995 Antiestrogenic properties of raloxifene. Pharmacology. 50:209-217.
9. Cohen BM, Berry L, Roethemeyer V, Smith D. 1992 Sonographic assessment of late proliferative phase endometrium during ovulation induction. J Reprod Med. 37:685-690.
10. Midgley AR, Jaffe RB. 1971 Regulation of human gonadotropins. X. Episodic fluctuation of LH during the menstrual cycle. J Clin Endocrinol Metab. 33:962-969.
11. Abraham GE, Manlimos FS, Garza R. 1977 Radioimmunoassay of steroids. In: Abraham GE, ed. Handbook of radioimmunoassay. New York: Marcel Dekker; 591-656.
12. Buster JE, Abraham GE. 1972 Radioimmunoassay of plasma dehydroepiandrosterone sulfate. Anal Lett. 5:543-551.
13. Cotran RS, Kumar V, Robbins SL, Schoen FJ. 1994 Robbins pathologic basis of disease. Philadelphia: Saunders; 17.
14. Noyes RW, Hertig AT, Rock J. 1950 Dating the endometrial biopsy. Fertil Steril. 1:3-25.
15. Buckley CH, Fox H. 1989 Biopsy pathology of the endometrium. New York: Raven Press; 56-63.
16. Yen SSC, Jaffe RB. 1991 Reproductive endocrinology. Philadelphia; Saunders; 579-582.
17. Baker VL, Jaffe RB. 1996 Clinical use of antiestrogens. Obstet Gynecol Surv. 51:45-59.
18. Jordan VC, Fritz NF, Langan-Fahey S, Thompson M, Tormey DC. 1991 Alteration of endocrine parameters in premenopausal women with breast cancer during long-term adjuvant therapy with tamoxifen as the single agent. J Natl Cancer Inst. 83:1488-1491.
19. Messinis IE, Nillius SJ. 1982 Comparison between tamoxifen and clomiphene for induction of ovulation. Acta Obstet Gynecol Scand. 61:377-379.
20. Jordan VC, Fritz NF, Tormey DC. 1987 Endocrine effects of adjuvant chemotherapy and long-term tamoxifen administration on node-positive patients with breast cancer. Cancer Res. 47:624-630.
21. Adashi EY. 1984 Clomiphene citrate: mechanisms and sites of action - a hypothesis revisited. Fertil Steril. 42:331-344.
22. Eden JA, Place J, Carter GD, Jones J, Alaghband-Zadeh J, Pawson ME. 1989 The effect of clomiphene citrate on follicular phase increase in endometrial thickness and uterine volume. Obstet Gynecol. 73:187-190.
23. Dickey RP, Olar TT, Taylor SN, Curole DN, Matulich EM. 1993 Relationship of endometrial thickness and pattern to fecundity in ovulation induction cycles: effect of clomiphene citrate alone and with human menopausal gonadotropin. Fertil Steril. 59:756-760.
24. Li TC, Warren MA, Murphy C, Sargeant S, Cooke, ID. 1992 A prospective, randomised, cross-over study comparing the effects of clomiphene citrate and cyclofenil on endometrial morphology in the luteal phase of normal, fertile women. Br J Obstet Gynaecol. 99:1008-1013.
25. Bryant HU, Glasebrook AL, Yang NA, Sato M. 1996 A pharmacological review of raloxifene. J Bone Miner Res. 14:1-9.
26. Gelety TJ, Buyalos RP. 1993 The effect of clomiphene citrate and menopausal gonadotropins on cervical mucus in ovulatory cycles. Fertil Steril. 60:471-476.
27. Butzow TL, Kettel LM, Yen SSC. 1995 Clomiphene citrate reduces serum insulin-like growth factor 1 and increases sex hormone-binding globulin levels in women with polycystic ovarian syndrome. Fertil Steril. 63:1200-1203.
28. Rose DP, Chlebowski RT, Connolly JM, Jones LA, Wynder EL. 1992 Effects of tamoxifen adjuvant therapy and a low-fat diet on serum binding proteins and estradiol bioavailability in postmenopausal breast cancer patients. Cancer Res. 52:5386-5390.